Session-Specific Learning Objectives

The learning objectives for LUPUS 2025 are designed to enhance knowledge, improve clinical practice, and foster interdisciplinary collaboration in the field of systemic lupus erythematosus. The congress will equip participants with cutting-edge insights, evidence-based strategies, and practical tools to advance lupus care worldwide.

Plenary Session: The Future in Lupus

- Explain the role of AI-powered precision medicine in autoimmune diseases.
- Discuss advancements in personalized medicine approaches for lupus care.

Plenary Session: Year in Review

- Summarize the key clinical and basic science findings in lupus research from the past year.
- Identify emerging challenges and opportunities in lupus management.

Scientific Session: The Future of Drug Trial Design in SLE

- Explore novel trial designs that enhance patient inclusiveness.
- Assess new outcome measures and endpoints to improve clinical research in lupus.

Scientific Session: Disease Heterogeneity

- Explain the role of transcriptional and immunophenotypic stratification in personalizing lupus treatment.
- Identify genetic and molecular factors that contribute to SLE heterogeneity.

Scientific Session: Pediatric Scientific Session – Outcomes and Targets in Children with SLE

- Evaluate treat-to-target strategies in pediatric lupus, including LLDAS (Lupus Low Disease Activity State) and other clinical targets, to optimize disease management and improve long-term outcomes.
- Assess key challenges in pediatric SLE, including neuropsychiatric manifestations, cardiovascular risks, and transition to adult care, to enhance early diagnosis, intervention, and comprehensive patient support.

Patient Session: Mental Health in SLE

- Identify common mental health challenges (e.g., anxiety, depression) in lupus patients.
- Evaluate strategies to enhance psychosocial support for SLE patients.

Fishbowl Discussion: What to Do When HCQ Needs to Be Stopped Due to Toxicity

- Recognize early signs of HCQ toxicity in lupus patients.
- Discuss alternative treatment strategies for patients who discontinue HCQ.

Scientific Session: New Biologics - Lupus Drug Pipeline in SLE

- Compare the efficacy and safety of current and emerging biologic treatments for lupus.
- Examine the impact of renal vs. non-r
- enal manifestations in lupus treatment decisions.

Scientific Session: OMERACT

- Describe the development and validation of OMERACT core domain sets for SLE clinical trials and their role in standardizing outcome measures.
- Evaluate the impact of patient-reported outcomes (PROs) in lupus research and clinical practice, and discuss their integration into future treatment strategies and clinical trials.

Debate Session: The Use of CNI in Lupus Nephritis

- Analyze the benefits and risks of calcineurin inhibitors in lupus nephritis management.
- Review the latest clinical data to determine the best candidates for CNI therapy.

Scientific Session: Cell Therapy in Lupus

- Discuss the mechanisms and potential applications of cell-based therapies in lupus.
- Evaluate clinical trial data on CAR-T and mesenchymal stem cell therapies.

Scientific Session: Overview of Treat-to-Target in Lupus

- Describe the concept of treat-to-target (T2T) in lupus management.
- Assess the feasibility of achieving remission or low disease activity (LLDAS) in clinical practice.

Scientific Session: Cognitive Impairment and Beyond

- Identify neurocognitive deficits associated with lupus.
- Assess the utility of functional MRI (fMRI) and imaging biomarkers in lupus brain research.

Plenary Session: Contrast LN Recommendations – EULAR, ACR, and KDIGO

- Compare the key differences in EULAR, ACR, and KDIGO guidelines for lupus nephritis.
- Evaluate the clinical implications of applying different guidelines in patient care.